Brought to you by 
Beam Therapeutics sublicenses Editas' gene editing technologies
31 May 2018
Executive Summary
Recently founded Beam Therapeutics Inc. sublicensed exclusive rights to intellectual property related to various genome editing technologies Editas Medicine Inc. had gained through previous deals with Harvard University, the Broad Institute, and Massachusetts General Hospital. Beam also signed a concurrent deal with the Broad Institute, Harvard, and MIT for additional base editing platforms.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Beam Therapeutics sublicenses Editas' gene editing technologies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice